Please visit answersincme.com/ZWK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology and oncology discusses B-cell maturation antigen (BCMA)–targeted strategies for the treatment of multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the latest evidence for investigational regimens containing BCMA-targeted immunotherapies for earlier lines of multiple myeloma (MM) treatment; Evaluate the clinical impact of combining late-stage emerging, BCMA-targeted strategies with standard of care (SOC) for earlier lines of MM treatment; and Identify strategies to optimally incorporate novel BCMA-containing therapies into the current treatment paradigm, as they become available, for patients with MM.